UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

________________________________

FORM 10-Q

________________________________


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June~~September 30, 2023


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-33958

SELLAS Life Sciences Group, Inc.

(Exact name of registrant as specified in its charter)


Delaware						20-8099512
(State of incorporation)						(I.R.S. Employer Identification No.)

7 Times Square, Suite 2503, New York, NY 10036

(646) 200-5278

(Address, including zip code, and telephone number, including

area code, of registrant's principal executive offices)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	SLS	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter time that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act:

Large accelerated filer

☐

Accelerated filer

☐

Non-accelerated filer

☒

Smaller reporting company

☒

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): ☐ Yes ☒ No

As of ~~August 9,~~November 8, 2023, SELLAS Life Sciences Group, Inc. had outstanding ~~28,347,920~~32,062,258 shares of common stock.

SELLAS LIFE SCIENCES GROUP, INC.

FORM 10-Q - Quarterly Report

For the Quarter Ended ~~June~~September 30, 2023

TABLE OF CONTENTS


		Page
	PART I - FINANCIAL INFORMATION
Item 1	Financial Statements	4
	Unaudited Consolidated Balance Sheets as of ~~June~~September 30, 2023 and December 31, 2022	4
	Unaudited Consolidated Statements of Operations for the Three and ~~Six~~Nine Months Ended ~~June~~September 30, 2023 and 2022	5
	Unaudited Consolidated Statements of Stockholders' (Deficit) Equity for the Three and ~~Six~~Nine Months Ended ~~June~~September 30, 2023 and 2022	6
	Unaudited Consolidated Statements of Cash Flows for the ~~Six~~Nine Months Ended ~~June~~September 30, 2023 and 2022	7
	Unaudited Notes to Consolidated Financial Statements	8
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19
Item 3	Quantitative and Qualitative Disclosures About Market Risk	2829
Item 4	Controls and Procedures	2829
	PART II - OTHER INFORMATION
Item 1	Legal Proceedings	3031
Item 1A	Risk Factors	3031
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	3031
Item 3	Defaults Upon Senior Securities	3031
Item 4	Mine Safety Disclosures	3031
Item 5	Other Information	3031
Item 6	Exhibits	3031

	Signatures

The names “SELLAS Life Sciences Group, Inc.,” “SELLAS,” the SELLAS logo, and other trademarks or service marks of SELLAS Life Sciences Group, Inc. appearing in this Quarterly Report on Form 10-Q are the property of SELLAS Life Sciences Group, Inc. Other trademarks, service marks or trade names appearing in this Quarterly Report on Form 10-Q are the property of their respective owners. We do not intend the use or display of other companies’ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of or by either of, these other companies.

Unless the context otherwise indicates, references in these notes to the “Company,” “we,” “us” or “our” refer to SELLAS Life Sciences Group, Inc. and its wholly owned subsidiaries.

SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS

This Quarterly Report on Form 10-Q includes forward-looking statements that reflect our current views with respect to our development programs, business strategy, business plan, financial performance and other future events. These statements include forward-looking statements both with respect to us, specifically, and our industry, in general. Such forward-looking statements include the words "expect," "intend,” "plan," "believe," "project," "estimate,” "may,” "should," "anticipate," "will" and similar statements of a future or forward-looking nature identify forward-looking statements and include, without limitation, statements regarding:

•our future financial and business performance;

•strategic plans for our business and product candidates;

•our ability to develop or commercialize products;

•the expected results and timing of clinical trials and nonclinical studies;

•our ability to comply with the terms of our license agreements;

•developments and projections relating to our competitors and industry;

•our expectations regarding our ability to obtain, develop and maintain intellectual property protection and not infringe on the rights of others;

•our ability to retain key scientific or management personnel;

•our future capital requirements and the timing of those requirements and sources and uses of cash;

•our ability to obtain funding for our operations; and

•changes in applicable laws or regulations.

These statements are subject to known and unknown risks, uncertainties and assumptions that could cause actual results to differ materially from those projected or otherwise implied by the forward-looking statements, including the following:

•risks associated with preclinical or clinical development and trials;

•changes in the assumptions underlying our expectations regarding our future business or business model;

•our ability to develop, manufacture and commercialize product candidates;

•general economic, financial, legal, political and business conditions and changes in domestic and foreign markets;

•changes in applicable laws or regulations;

•the impact of natural disasters, including climate change, and the impact of health epidemics, including the COVID-19 pandemic, on our business;

•the size and growth potential of the markets for our products, and our ability to serve those markets;

•market acceptance of our planned products;

•our ability to raise capital;

•the possibility that we may be adversely affected by other economic, business, and/or competitive factors; and

•other risks and uncertainties set forth in this report in the section entitled “Risk Factors.”

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. There are or will be important factors that could cause actual results to differ materially from those indicated in these statements. These factors include, but are not limited to, those factors set forth in the sections captioned "Business – Overview,” “Risk Factors,” “Legal Proceedings,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in this Quarterly Report on Form 10-Q, in our Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the Securities and Exchange Commission ("SEC") on March 16, 2023 ("2022 Annual Report") and in our other public filings with the SEC, all of which you should review carefully. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

PART I FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SELLAS LIFE SCIENCES GROUP, INC.

CONSOLIDATED BALANCE SHEETS

(Amounts in thousands, except share and per share data)

(Unaudited)


		June 30, 2023		December 31, 2022			September 30, 2023			December 31, 2022

ASSETS	ASSETS								ASSETS
Current assets:	Current assets:					Current assets:
Cash and cash equivalents	Cash and cash equivalents	$	13,807	$	17,125	Cash and cash equivalents	$	3,969		$	17,125
Restricted cash and cash equivalents	Restricted cash and cash equivalents	100		100		Restricted cash and cash equivalents	100			100
Prepaid expenses and other current assets	Prepaid expenses and other current assets	1,674		531		Prepaid expenses and other current assets	1,134			531
Total current assets	Total current assets	15,581		17,756		Total current assets	5,203			17,756
Operating lease right-of-use assets	Operating lease right-of-use assets	690		874		Operating lease right-of-use assets	592			874
Goodwill	Goodwill	1,914		1,914		Goodwill	1,914			1,914
Deposits and other assets	Deposits and other assets	381		399		Deposits and other assets	377			399
Total assets	Total assets	$	18,566	$	20,943	Total assets	$	8,086		$	20,943
LIABILITIES AND STOCKHOLDERS’ EQUITY
LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY						LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY
Current liabilities:	Current liabilities:					Current liabilities:
Accounts payable	Accounts payable	$	3,734	$	3,357	Accounts payable	$	4,340		$	3,357
Accrued expenses and other current liabilities	Accrued expenses and other current liabilities	6,240		6,286		Accrued expenses and other current liabilities	6,929			6,286
Operating lease liabilities	Operating lease liabilities	447		372		Operating lease liabilities	466			372
Acquired in-process research and development payable	Acquired in-process research and development payable	3,000		5,500		Acquired in-process research and development payable	—			5,500
Total current liabilities	Total current liabilities	13,421		15,515		Total current liabilities	11,735			15,515
Operating lease liabilities, non-current	Operating lease liabilities, non-current	302		573		Operating lease liabilities, non-current	178			573
Warrant liability	Warrant liability	—		4		Warrant liability	—			4
Total liabilities	Total liabilities	13,723		16,092		Total liabilities	11,913			16,092
Commitments and contingencies (Note 7)	Commitments and contingencies (Note 7)					Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; Series A convertible preferred stock, 17,500 shares designated; no shares issued and outstanding at June 30, 2023 and December 31, 2022		—		—
Common stock, $0.0001 par value; 350,000,000 shares authorized, 28,347,920 and 21,005,405 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively		3		2
Stockholders’ (deficit) equity:						Stockholders’ (deficit) equity:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; Series A convertible preferred stock, 17,500 shares designated; no shares issued and outstanding at September 30, 2023 and December 31, 2022						Preferred stock, $0.0001 par value; 5,000,000 shares authorized; Series A convertible preferred stock, 17,500 shares designated; no shares issued and outstanding at September 30, 2023 and December 31, 2022	—			—
Common stock, $0.0001 par value; 350,000,000 shares authorized, 28,393,958 and 21,005,405 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively						Common stock, $0.0001 par value; 350,000,000 shares authorized, 28,393,958 and 21,005,405 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	3			2
Additional paid-in capital	Additional paid-in capital	204,681		184,753		Additional paid-in capital	205,278			184,753
Accumulated deficit	Accumulated deficit	(199,841)		(179,904)		Accumulated deficit	(209,108)			(179,904)
Total stockholders’ equity		4,843		4,851
Total liabilities and stockholders’ equity		$	18,566	$	20,943
Total stockholders’ (deficit) equity						Total stockholders’ (deficit) equity	(3,827)			4,851
Total liabilities and stockholders’ (deficit) equity						Total liabilities and stockholders’ (deficit) equity	$	8,086		$	20,943

See accompanying notes to these unaudited consolidated financial statements.

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands, except share and per share data)

(Unaudited)


		Three Months Ended June 30,				Six Months Ended June 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2023		2022		2023		2022			2023		2022		2023		2022
Licensing revenue	Licensing revenue	$	—	$	—	$	—	$	1,000	Licensing revenue	$	—	$	—	$	—	$	1,000
Operating expenses:	Operating expenses:									Operating expenses:
Cost of licensing revenue	Cost of licensing revenue	—		—		—		100		Cost of licensing revenue	—		—		—		100
Research and development	Research and development	5,923		5,529		13,097		10,140		Research and development	5,813		4,282		18,910		14,422
General and administrative	General and administrative	3,127		3,094		7,234		6,118		General and administrative	3,548		2,864		10,782		8,982
Acquired in-process research and development	Acquired in-process research and development	—		—		—		10,000		Acquired in-process research and development	—		—		—		10,000
Total operating expenses	Total operating expenses	9,050		8,623		20,331		26,358		Total operating expenses	9,361		7,146		29,692		33,504
Operating loss	Operating loss	(9,050)		(8,623)		(20,331)		(25,358)		Operating loss	(9,361)		(7,146)		(29,692)		(32,504)
Non-operating income:	Non-operating income:									Non-operating income:
Change in fair value of warrant liability	Change in fair value of warrant liability	2		48		4		37		Change in fair value of warrant liability	—		2		4		39
Change in fair value of contingent consideration	Change in fair value of contingent consideration	—		115		—		115		Change in fair value of contingent consideration	—		11		—		126
Interest income	Interest income	208		46		390		48		Interest income	94		111		484		159
Total non-operating income	Total non-operating income	210		209		394		200		Total non-operating income	94		124		488		324
Net loss	Net loss	$	(8,840)	$	(8,414)	$	(19,937)	$	(25,158)	Net loss	$	(9,267)	$	(7,022)	$	(29,204)	$	(32,180)

Per share information:	Per share information:									Per share information:
Net loss per common share, basic and diluted	Net loss per common share, basic and diluted	$	(0.31)	$	(0.41)	$	(0.77)	$	(1.39)	Net loss per common share, basic and diluted	$	(0.33)	$	(0.34)	$	(1.09)	$	(1.70)
Weighted-average common shares outstanding, basic and diluted	Weighted-average common shares outstanding, basic and diluted	28,347,920		20,286,624		25,961,001		18,104,176		Weighted-average common shares outstanding, basic and diluted	28,355,427		20,562,351		26,767,914		18,932,571

See accompanying notes to these unaudited consolidated financial statements.

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY

(Amounts in thousands, except share amounts)

(Unaudited)


		Three Months Ended June 30, 2023															Three Months Ended September 30, 2023
		Common Stock			Additional Paid-In Capital				Accumulated Deficit					Total Stockholders' Equity			Common Stock							Additional Paid-In Capital			Accumulated Deficit			Total Stockholders' (Deficit) Equity
		Shares	Amount										Shares					Amount
Balance at March 31, 2023		28,347,920	$	3			$	204,167			$	(191,001)					$	13,169
Balance at June 30, 2023																Balance at June 30, 2023	28,347,920				$	3			$	204,681		$	(199,841)		$	4,843
Issuance of common stock under employee stock purchase plan																Issuance of common stock under employee stock purchase plan	46,038				—			54			—			54
Stock-based compensation	Stock-based compensation	—	—		514				—					514		Stock-based compensation	—				—			543			—			543
Net loss	Net loss	—	—		—				(8,840)					(8,840)		Net loss	—				—			—			(9,267)			(9,267)
Balance at June 30, 2023		28,347,920	$	3	$	204,681			$	(199,841)				$	4,843
Balance at September 30, 2023																Balance at September 30, 2023	28,393,958				$	3		$	205,278		$	(209,108)		$	(3,827)

		Six Months Ended June 30, 2023															Nine Months Ended September 30, 2023
		Common Stock			Additional Paid-In Capital				Accumulated Deficit					Total Stockholders' Equity			Common Stock							Additional Paid-In Capital			Accumulated Deficit			Total Stockholders' (Deficit) Equity
		Shares	Amount										Shares					Amount
Balance at December 31, 2022	Balance at December 31, 2022	21,005,405	$	2			$	184,753			$	(179,904)					$	4,851	Balance at December 31, 2022	21,005,405			$		2		$	184,753		$	(179,904)		$	4,851
Issuance of common stock and common stock warrants, net of issuance costs	Issuance of common stock and common stock warrants, net of issuance costs	7,220,217	1		18,553				—					18,554		Issuance of common stock and common stock warrants, net of issuance costs	7,220,217				1			18,553			—			18,554
Issuance of common stock, net of issuance costs	Issuance of common stock, net of issuance costs	76,882			268									268		Issuance of common stock, net of issuance costs	76,882				—			268			—			268
Issuance of common stock under employee stock purchase plan	Issuance of common stock under employee stock purchase plan	45,416	—		53				—					53		Issuance of common stock under employee stock purchase plan	91,454				—			107			—			107
Stock-based compensation	Stock-based compensation	—	—		1,054				—					1,054		Stock-based compensation	—				—			1,597			—			1,597
Net loss	Net loss	—	—		—				(19,937)					(19,937)		Net loss	—				—			—			(29,204)			(29,204)
Balance at June 30, 2023		28,347,920	$	3	$	204,681			$	(199,841)				$	4,843
Balance at September 30, 2023																Balance at September 30, 2023	28,393,958				$	3		$	205,278		$	(209,108)		$	(3,827)


		Three Months Ended June 30, 2022															Three Months Ended September 30, 2022
		Common Stock			Additional Paid-In Capital				Accumulated Deficit					Total Stockholders' Equity			Common Stock							Additional Paid-In Capital			Accumulated Deficit			Total Stockholders' Equity
		Shares	Amount										Shares					Amount
Balance at March 31, 2022		15,905,999	$	2			$	159,370			$	(155,347)					$	4,025
Balance at June 30, 2022																Balance at June 30, 2022	20,551,918				$	2			$	182,816		$	(163,761)		$	19,057
Issuance of common stock and common stock warrants, net of issuance costs	Issuance of common stock and common stock warrants, net of issuance costs	4,629,630	—		22,946				—					22,946		Issuance of common stock and common stock warrants, net of issuance costs	21,602				—			69			—			69
Issuance of common stock, net of issuance costs		16,289			50									50
Issuance of common stock under employee stock purchase plan																Issuance of common stock under employee stock purchase plan	14,727							38						38
Stock-based compensation	Stock-based compensation	—	—		450				—					450		Stock-based compensation	—				—			455			—			455
Net loss	Net loss	—	—		—				(8,414)					(8,414)		Net loss	—				—			—			(7,022)			(7,022)
Balance at June 30, 2022		20,551,918	$	2	$	182,816			$	(163,761)				$	19,057
Balance at September 30, 2022																Balance at September 30, 2022	20,588,247				$	2		$	183,378		$	(170,783)		$	12,597

		Six Months Ended June 30, 2022															Nine Months Ended September 30, 2022
		Common Stock			Additional Paid-In Capital				Accumulated Deficit					Total Stockholders' Equity			Common Stock							Additional Paid-In Capital			Accumulated Deficit			Total Stockholders' Equity
		Shares	Amount										Shares					Amount
Balance at December 31, 2021	Balance at December 31, 2021	15,895,637	$	2			$	158,948			$	(138,603)					$	20,347	Balance at December 31, 2021	15,895,637			$		2		$	158,948		$	(138,603)		$	20,347
Issuance of common stock and common stock warrants, net of issuance costs	Issuance of common stock and common stock warrants, net of issuance costs	4,629,630	—		22,946				—					22,946		Issuance of common stock and common stock warrants, net of issuance costs	4,629,630				—			22,946			—			22,946
Issuance of common stock, net of issuance costs	Issuance of common stock, net of issuance costs	16,289			50									50		Issuance of common stock, net of issuance costs	37,891							119						119
Issuance of common stock under employee stock purchase plan	Issuance of common stock under employee stock purchase plan	10,362	—		47				—					47		Issuance of common stock under employee stock purchase plan	25,089				—			85			—			85
Stock-based compensation	Stock-based compensation	—	—		825				—					825		Stock-based compensation	—				—			1,280			—			1,280
Net loss	Net loss	—	—		—				(25,158)					(25,158)		Net loss	—				—			—			(32,180)			(32,180)
Balance at June 30, 2022		20,551,918	$	2	$	182,816			$	(163,761)				$	19,057
Balance at September 30, 2022																Balance at September 30, 2022	20,588,247				$	2		$	183,378		$	(170,783)		$	12,597

See accompanying notes to these unaudited consolidated financial statements.

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts in thousands)

(Unaudited)


		For the Six Months Ended June 30,					Nine Months Ended September 30,
		2023		2022			2023		2022
Cash flows from operating activities:	Cash flows from operating activities:					Cash flows from operating activities:
Net loss	Net loss	$	(19,937)	$	(25,158)	Net loss	$	(29,204)	$	(32,180)
Adjustment to reconcile net loss to net cash used in operating activities:	Adjustment to reconcile net loss to net cash used in operating activities:					Adjustment to reconcile net loss to net cash used in operating activities:
Acquired in-process research and development expense	Acquired in-process research and development expense	—		10,000		Acquired in-process research and development expense	—		10,000
Non-cash stock-based compensation	Non-cash stock-based compensation	1,054		825		Non-cash stock-based compensation	1,597		1,280
Non-cash lease expense	Non-cash lease expense	245		127		Non-cash lease expense	367		334
Change in fair value of common stock warrants	Change in fair value of common stock warrants	(4)		(37)		Change in fair value of common stock warrants	(4)		(39)
Change in fair value of contingent consideration	Change in fair value of contingent consideration	—		(115)		Change in fair value of contingent consideration	—		(126)
Changes in operating assets and liabilities:	Changes in operating assets and liabilities:					Changes in operating assets and liabilities:
Prepaid expenses and other assets	Prepaid expenses and other assets	(1,125)		19		Prepaid expenses and other assets	(581)		505
Accounts payable	Accounts payable	377		1,195		Accounts payable	983		(17)
Accrued expenses and other current liabilities	Accrued expenses and other current liabilities	(46)		366		Accrued expenses and other current liabilities	643		1,930
Operating lease liabilities	Operating lease liabilities	(257)		(133)		Operating lease liabilities	(386)		(344)
Net cash used in operating activities	Net cash used in operating activities	(19,693)		(12,911)		Net cash used in operating activities	(26,585)		(18,657)
Cash flows from investing activities:	Cash flows from investing activities:					Cash flows from investing activities:
Cash paid for acquisition of in-process research and development	Cash paid for acquisition of in-process research and development	(2,500)		(4,500)		Cash paid for acquisition of in-process research and development	(5,500)		(4,500)
Net cash used in investing activities	Net cash used in investing activities	(2,500)		(4,500)		Net cash used in investing activities	(5,500)		(4,500)
Cash flows from financing activities:	Cash flows from financing activities:					Cash flows from financing activities:
Proceeds from issuance of common stock and common stock warrants, net of issuance costs	Proceeds from issuance of common stock and common stock warrants, net of issuance costs	18,554		22,946		Proceeds from issuance of common stock and common stock warrants, net of issuance costs	18,554		22,946
Proceeds from issuance of common stock, net of issuance costs	Proceeds from issuance of common stock, net of issuance costs	268		50		Proceeds from issuance of common stock, net of issuance costs	268		119
Proceeds from employee stock purchases	Proceeds from employee stock purchases	53		47		Proceeds from employee stock purchases	107		85
Net cash provided by financing activities	Net cash provided by financing activities	18,875		23,043		Net cash provided by financing activities	18,929		23,150
Net (decrease) increase in cash, cash equivalents, restricted cash, and restricted cash equivalents		(3,318)		5,632
Net decrease in cash, cash equivalents, restricted cash, and restricted cash equivalents						Net decrease in cash, cash equivalents, restricted cash, and restricted cash equivalents	(13,156)		(7)
Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of period	Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of period	17,225		21,455		Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of period	17,225		21,455
Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of period	Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of period	$	13,907	$	27,087	Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of period	$	4,069	$	21,448

Supplemental disclosure of cash flow information:	Supplemental disclosure of cash flow information:					Supplemental disclosure of cash flow information:
Cash received during the period for interest	Cash received during the period for interest	$	390	$	48	Cash received during the period for interest	$	484	$	159
Supplemental disclosure of non-cash investing and financing activities:	Supplemental disclosure of non-cash investing and financing activities:					Supplemental disclosure of non-cash investing and financing activities:
Non-cash acquisition of in-process research and development	Non-cash acquisition of in-process research and development	$	—	$	5,500	Non-cash acquisition of in-process research and development	$	—	$	5,500
Increase in operating lease right-of-use assets and current and non-current operating lease liabilities	Increase in operating lease right-of-use assets and current and non-current operating lease liabilities	$	—	$	449	Increase in operating lease right-of-use assets and current and non-current operating lease liabilities	$	—	$	449

See accompanying notes to these unaudited consolidated financial statements.

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Description of Business

Overview

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S ("GPS"), is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center ("MSK") and targets the Wilms Tumor 1 ("WT1") protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. SELLAS' second product candidate is SLS009 (formerly GFH009), a small molecule, highly selective cyclin-dependent kinase 9 ("CDK9") inhibitor, which the Company licensed from GenFleet Therapeutics (Shanghai), Inc. ("GenFleet"), for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau and Taiwan ("SLS009 Territory").

2. Liquidity

Since inception, the Company has incurred recurring losses and negative cash flows from operations and, as of ~~June~~September 30, 2023, has an accumulated deficit of ~~$199.8~~$209.1 million. During the ~~six~~nine months ended ~~June~~September 30, 2023, the Company incurred a net loss of ~~$19.9~~$29.2 million, and used ~~$19.7~~$26.6 million of cash in operations. The Company expects to continue to generate operating losses and negative cash flows from operations for the next few years and will need additional funding to support its planned operating activities through profitability. The transition to profitability is dependent upon the successful development, approval, and commercialization of the Company's product candidates and the achievement of a level of revenues adequate to support its cost structure.

On October 30, 2023, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a single institutional investor (the "Investor"), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investor (the “October 2023 Registered Direct Offering”), 3,100,000 shares of its common stock and 552,300 pre-funded warrants exercisable for shares of common stock, together with accompanying warrants to purchase an aggregate of 3,652,300 shares of common stock. Each share of common stock and accompanying warrant were sold together at a combined purchase price of $1.0952 and each pre-funded warrant and accompanying warrant were sold together at a combined purchase price of $1.0951. The aggregate gross proceeds to the Company from the October 2023 Registered Direct Offering were approximately $4.0 million, before deducting placement agents' fees and related offering expenses. Subsequent to the closing of the October 2023 Registered Direct Offering, all of the pre-funded warrants were exercised into shares of common stock by the Investor.

On February 28, 2023, the Company consummated an underwritten public offering (the "February 2023 Offering"), issuing 7,220,217 shares of common stock and accompanying common stock warrants to purchase an aggregate of 7,220,217 shares of common stock. The shares of common stock and accompanying common stock warrants were sold at a combined price of $2.77 per share and accompanying common stock warrant. Each common stock warrant sold with the shares of common stock represents the right to purchase one share of the Company’s common stock at an exercise price of $2.77 per ~~share.~~share, which was reduced to an exercise price of $1.35 per share in October 2023, and further reduced to an exercise price of $0.9702 per share in November 2023. The common stock warrants are exercisable immediately and will expire on February 28, 2028, five years from the date of issuance. The net proceeds to the Company from the February 2023 Offering were approximately $18.5 million, after deducting underwriting discounts and commissions, offering expenses, and excluding the exercise of any warrants.

On April 16, 2021, the Company entered into a Controlled Equity OfferingSM Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald & Co. (the "Agent"). From time to time during the term of the Sales Agreement, subject to certain restrictions, the Company may offer and sell shares of common stock having an aggregate offering price up to a total of $50.0 million in gross proceeds. The Agent will collect a fee equal to 3% of the gross sales price of all shares of common stock sold. Shares of common stock sold under the Sales Agreement are offered and sold pursuant to the Company's registration statement on Form S-3, which was filed with the SEC on April 16, 2021 and declared effective on April 29, 2021. During the ~~six~~nine months ended ~~June~~September 30, 2023, the

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued

(Unaudited)

Company sold a total of 76,882 shares of common stock pursuant to the Sales Agreement at an average price of $3.59 per share for aggregate net proceeds of approximately $0.3 million. ~~There remains approximately $39.2 million available for future sales~~Subsequent to September 30, 2023, the Company sold a total of 16,000 shares of common stock ~~under the Sales Agreement. Other than~~pursuant to the Sales Agreement ~~the Company currently does not have any commitments to obtain additional funds.~~for aggregate net proceeds of approximately $21,000.

In December 2020, the Company, together with its wholly-owned subsidiary, SLSG Limited, LLC, entered into an Exclusive License Agreement (the “3DMed License Agreement”) with 3D Medicines Inc. ("3DMed"), pursuant to which the Company granted 3DMed a sublicensable, royalty-bearing license, under certain intellectual property owned or controlled by the Company, to develop, manufacture and have manufactured, and commercialize GPS and heptavalent GPS product candidates for all therapeutic and other diagnostic uses in mainland China, Hong Kong, Macau and Taiwan ("3DMed Territory"). To date, the Company has received $10.5 million in upfront payments and certain technology transfer and regulatory milestones. ~~The participation of~~In November 2022, the Company announced that the Company has agreed with 3DMed for 3DMed to participate in the ~~Company's~~ REGAL ~~Phase 3 clinical trial~~study through the inclusion of approximately 20-25 patients from mainland China. Such participation by 3DMed, which the Company expects to occur in ~~China~~the fourth quarter of 2023, subject to any further delays due to supply chain or other operational reasons, will trigger two development milestone payments totaling $13.0 million ~~to the Company,~~ which ~~the Company expects to receive in the third quarter of 2023.~~has been agreed with 3DMed. A total of $191.5 million in potential

~~Table of Contents~~

~~SELLAS LIFE SCIENCES GROUP, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued~~

~~(Unaudited)~~

future development, regulatory, and sales milestones, not including future royalties, remains under the 3DMed License Agreement as of ~~June~~September 30, 2023, which milestones are all variable in nature and not under the Company's control.

As of ~~June~~September 30, 2023, the Company had cash and cash equivalents of approximately ~~$13.8~~$4.0 million and restricted cash and cash equivalents of $0.1 million. In accordance with Accounting Standards Codification ("ASC") 205-40, Presentation of Financial Statements - Going Concern, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company expects its cash and cash equivalents, together with the net proceeds from the October 2023 Registered Direct Offering, will not be sufficient to fund its current planned operations for at least the next twelve months from the date of issuance of these consolidated financial statements. The $13.0 million of development milestone payments to the Company triggered by 3DMed's participation in the REGAL study through the enrollment of patients in China are variable in nature and not under the Company's control, and therefore ~~are not~~cannot be included in the Company's going concern assumption.

The Company will require substantial additional financing to commercially develop any current or future product candidates. If the Company is unable to obtain additional funding on a timely basis, it will be required to scale back its plans and place certain activities on hold. Other than the Sales Agreement, the Company currently does not have any commitments to obtain additional funds. The Company's management continues to evaluate different strategies to obtain the required funding for future operations. These strategies may include utilizing the Sales Agreement or public and private placements of equity and/or debt securities, which may be subject to lock-up, as well as payments from potential strategic research and development collaborations ~~and~~or licensing and/or marketing arrangements with pharmaceutical companies. Additionally, the Company may continue to pursue discussions with global and regional pharmaceutical companies for licensing and/or co-development rights to its product candidates. The Company has prepared its consolidated financial statements assuming that it will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

3. Basis of Presentation and Significant Accounting Policies

The Company's complete summary of significant accounting policies can be found in "Item 8. Financial Statements and Supplementary Data - Note 3. Basis of Presentation and Significant Accounting Policies" in the audited annual consolidated financial statements included in the 2022 Annual Report. The significant accounting policies summarized and included in the 2022 Annual Report have not materially changed, except as set forth below.

Basis of Presentation

The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”). Any reference in these notes to applicable

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued

(Unaudited)

guidance is meant to refer to U.S. GAAP as found in the ASC and Accounting Standards Updates ("ASUs") of the Financial Accounting Standards Board ("FASB").

Principles of Consolidation

The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation. Unless the context otherwise indicates, reference in these notes to the "Company" refer to SELLAS Life Sciences Group, Inc., and its wholly owned subsidiaries, SELLAS Life Sciences Group, Ltd., a privately held Bermuda exempted company, SLSG Limited, LLC, Sellas Life Sciences Limited, and Apthera, Inc. The functional currency of the Company's non-U.S. operations is the U.S. dollar.

Unaudited Interim Results

These consolidated financial statements and accompanying notes should be read in conjunction with the Company's annual consolidated financial statements and the notes thereto included in the 2022 Annual Report. The accompanying consolidated financial statements as of ~~June~~September 30, 2023 and for the three and ~~six~~nine months ended ~~June~~September 30, 2023 and 2022, are unaudited, but include all adjustments, consisting of normal recurring entries, that

~~Table of Contents~~

~~SELLAS LIFE SCIENCES GROUP, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued~~

~~(Unaudited)~~

management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of December 31, 2022 have been derived from the audited financial statements as of that date.

Reclassification

Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on the Company's loss from operations, net loss, and net loss per share.

Net Loss Per Share

Net loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share, the weighted average number of shares remains the same for both calculations due to the fact that, when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.

The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands):


		Six Months Ended June 30,			Nine Months Ended September 30,
		2023	2022		2023	2022
Common stock warrants	Common stock warrants	12,361	5,148	Common stock warrants	12,221	5,148
Stock options	Stock options	1,665	1,012	Stock options	1,643	1,071
Restricted stock units ("RSUs")	Restricted stock units ("RSUs")	433	297	Restricted stock units ("RSUs")	433	297
		14,459	6,457		14,297	6,516

4. Fair Value Measurements

The following tables present information about the Company's assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets (in thousands):

Description June 30, 2023 Quoted Prices In
Active Markets
(Level 1) Significant Other
Observable
Inputs (Level 2) Unobservable
Inputs
(Level 3)
Assets:
Cash equivalents $ 13,192 $ 13,192 $ — $ —
Restricted cash equivalents 100 100 — —
Total assets measured and recorded at fair value $ 13,292 $ 13,292 $ — $ —
Liabilities:
Warrant liability $ — $ — $ — $ —
Total liabilities measured and recorded at fair value $ — $ — $ — $ —

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued

(Unaudited)


Description	September 30, 2023		Quoted Prices In Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Unobservable Inputs (Level 3)
Assets:
Cash equivalents	$	3,006	$	3,006	$	—	$	—
Restricted cash equivalents	100		100		—		—
Total assets measured and recorded at fair value	$	3,106	$	3,106	$	—	$	—
Liabilities:
Warrant liability	$	—	$	—	$	—	$	—
Total liabilities measured and recorded at fair value	$	—	$	—	$	—	$	—


Description	December 31, 2022		Quoted Prices In Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Unobservable Inputs (Level 3)
Assets:
Cash equivalents	$	16,609	$	16,609	$	—	$	—
Restricted cash equivalents	100		100		—		—
Total assets measured and recorded at fair value	$	16,709	$	16,709	$	—	$	—
Liabilities:
Warrant liability	$	4	$	—	$	—	$	4
Total liabilities measured and recorded at fair value	$	4	$	—	$	—	$	4

The Company did not transfer any financial instruments into or out of Level 3 classification during the ~~six~~nine months ended ~~June~~September 30, 2023 or during the year ended December 31, 2022. See Note 9, Warrants to Acquire Shares of Common Stock, for a reconciliation of the changes in the fair value of the warrant liability for the ~~six~~nine months ended ~~June~~September 30, 2023.

5. Acquired In-Process Research and Development

Exclusive License Agreement with GenFleet Therapeutics (Shanghai) Inc.

On March 31, 2022, the Company entered into an exclusive license agreement with GenFleet pursuant to which GenFleet granted to the Company a sublicensable royalty-bearing license under certain of its intellectual property, to develop, manufacture, and commercialize SLS009 for the treatment, diagnosis or prevention of disease in humans and animals in the SLS009 Territory.

In consideration for the exclusive license, the Company agreed to pay to GenFleet (i) an upfront and technology transfer fee of $10.0 million, ~~$7.0 million~~all of which ~~was~~has been paid as of ~~June~~September 30, ~~2023 and the remaining $3.0 million of which is expected to be paid during the third quarter of~~ 2023, (ii) development and regulatory milestone payments for up to three indications totaling up to $48.0 million in the aggregate upon the achievement of such milestones, and (iii) sales milestone payments totaling up to $92.0 million in the aggregate upon the achievement of certain net sales thresholds in a given calendar year. The Company ~~has~~ also agreed to pay GenFleet single-digit tiered royalties based upon a percentage of annual net sales, with the royalty rate escalating based on the level of annual net sales of SLS009 in the SLS009 Territory ranging from the low to high single digits.

During the ~~six~~nine months ended ~~June~~September 30, 2022, the Company expensed $10.0 million related to the acquired technology as in-process research and development based on the assessment that the technology has no alternative future ~~use, $7.0 million of which has been paid as of June~~use. During the three and nine months ended September 30, 2023, ~~and~~ the Company ~~has recorded an acquired in-process research and development payable as~~made cash payments of ~~June 30, 2023 for the remaining~~ $3.0 million ~~which is expected~~and $5.5 million, respectively, pursuant to ~~be paid during~~ the ~~third quarter of 2023.~~exclusive license agreement.

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued

(Unaudited)

6. Balance Sheet Accounts

Prepaid expenses and other current assets consist of the following (in thousands):


		June 30, 2023		December 31, 2022			September 30, 2023		December 31, 2022
Insurance	Insurance	$	1,123	$	219	Insurance	$	596	$	219
Clinical development	Clinical development	375		184		Clinical development	425		184
Professional fees	Professional fees	176		82		Professional fees	113		82
Other	Other	—		46		Other	—		46
Prepaid expenses and other current assets	Prepaid expenses and other current assets	$	1,674	$	531	Prepaid expenses and other current assets	$	1,134	$	531

Accrued expenses and other current liabilities consist of the following (in thousands):


		June 30, 2023		December 31, 2022			September 30, 2023		December 31, 2022
Clinical trial costs	Clinical trial costs	$	4,839	$	4,509	Clinical trial costs	$	4,864	$	4,509
Compensation and related benefits	Compensation and related benefits	1,111		1,439		Compensation and related benefits	1,547		1,439
Professional fees	Professional fees	208		338		Professional fees	304		338
Other	Other	82		—		Other	214		—
Accrued expenses and other current liabilities	Accrued expenses and other current liabilities	$	6,240	$	6,286	Accrued expenses and other current liabilities	$	6,929	$	6,286

7. Commitments and Contingencies

Leases

The Company has a non-cancelable operating lease for certain executive, administrative, and general business office space for its headquarters in New York, New York, which began on June 5, 2020, was amended in February 2022 to add additional space, and has a term through December 31, 2024. The Company assessed the lease amendment for the additional space and determined it should be accounted for as a separate contract.

The weighted average discount rate of the Company's operating leases under FASB Topic ASC 842, Leases ("ASC 842") is approximately 13.95%. As of ~~June~~September 30, 2023, the leases have a remaining term of ~~1.5~~1.25 years.

Rent expense related to the Company's operating leases was approximately $0.1 million for each of the three months ended ~~June~~September 30, 2023 and 2022, and ~~$0.2~~$0.4 million and $0.3 million for ~~each of~~ the ~~six~~nine months ended ~~June~~September 30, 2023 and ~~2022.~~2022, respectively.

The Company made cash payments related to its operating leases of approximately $0.1 million for each of the three months ended ~~June~~September 30, 2023 and 2022, and ~~$0.3~~$0.4 million and ~~$0.2~~$0.3 million for the ~~six~~nine months ended ~~June~~September 30, 2023 and 2022, respectively.

Future minimum lease payments are as follows as of ~~June~~September 30, 2023 (in thousands):


Future minimum lease payments:	Future minimum lease payments:			Future minimum lease payments:
2023 (remaining)	2023 (remaining)	$	261	2023 (remaining)	$	132
2024	2024	533		2024	533
Total future minimum lease payments	Total future minimum lease payments	794		Total future minimum lease payments	665
Less: imputed interest	Less: imputed interest	(45)		Less: imputed interest	(21)
Current and non-current operating lease liabilities	Current and non-current operating lease liabilities	$	749	Current and non-current operating lease liabilities	$	644

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued

(Unaudited)

Legal Proceedings

From time to time, the Company is subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business, which may include employment matters, breach of contract disputes and stockholder litigation. Such actions and proceedings are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. The Company records a liability in its consolidated financial statements for costs related to claims, including future legal costs, settlements and judgments, when the Company has assessed that a loss is probable and an amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, the Company records the most probable estimate of the loss or the minimum amount when no amount within the range is a better estimate than any other amount. The Company discloses a contingent liability even if the liability is not probable or the amount is not estimable, or both, if there is a reasonable possibility that a material loss may have been incurred. As of ~~June~~September 30, 2023, there was no pending or threatened litigation.

8. Stockholders’ Equity

Preferred Stock

The Company has authorized up to 5,000,000 shares of preferred stock, $0.0001 par value per share, for issuance. There were no preferred shares outstanding as of ~~June~~September 30, 2023 and December 31, 2022.

Common Stock

The Company has authorized up to 350,000,000 shares of common stock, $0.0001 par value per share, for issuance.

As of ~~June~~September 30, 2023, the Company has shares of common stock reserved for future issuance as follows (in thousands):


Warrants outstanding			~~12,361~~12,221
Stock options outstanding			~~1,665~~1,643
RSUs outstanding			433
Shares reserved for future issuance under the ~~Company’s 2019~~2023 Amended and Restated Equity Incentive Plan			~~3,883~~3,905
Shares reserved for future issuance under the 2021 Employee Stock Purchase Plan			~~229~~183
Total common stock reserved for future issuance			~~18,571~~18,385

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued

(Unaudited)

9. Warrants to Acquire Shares of Common Stock

Warrants Outstanding

The following is a summary of the activity of the Company's warrants to acquire shares of common stock for the ~~six~~nine months ended ~~June~~September 30, 2023 (in thousands):


Warrant Issuance	Warrant Issuance	Outstanding, December 31, 2022	Granted	Outstanding, June 30, 2023	Exercise Price per Share		Expiration	Warrant Issuance	Outstanding, December 31, 2022	Granted	Expired	Outstanding, September 30, 2023	Exercise Price per Share		Expiration
Warrants classified as equity:	Warrants classified as equity:							Warrants classified as equity:
February 2023 Offering	February 2023 Offering	—	7,220	7,220	$	2.77	February 2028	February 2023 Offering	—	7,220	—	7,220	$	2.77	February 2028
April 2022 Offering	April 2022 Offering	4,630	—	4,630	$	4.08	April 2027	April 2022 Offering	4,630	—	—	4,630	$	4.08	April 2027
January 2020 Offering	January 2020 Offering	309	—	309	$	3.93	July 2025	January 2020 Offering	309	—	—	309	$	3.93	July 2025
July 2020 PIPE Offering	July 2020 PIPE Offering	25	—	25	$	3.30	August 2025	July 2020 PIPE Offering	25	—	—	25	$	3.30	August 2025
July 2018 Offering		132	—	132	$	7.50	July 2023
March 2019 Exercise Agreement		30	—	30	$	7.50	March 2024

Other	Other	2	—	2	$	7.50	June 2024	Other	164	—	(133)	31	$	7.50	March 2024 - June 2024
		5,128	7,220	12,348					5,128	7,220	(133)	12,215
Warrants classified as liability	Warrants classified as liability	13	—	13	$	7.50	September 2023 - November 2023	Warrants classified as liability	13	—	(7)	6	$	7.50	November 2023
		5,141	7,220	12,361					5,141	7,220	(140)	12,221

The exercise price per share of the common stock warrants issued in the February 2023 Offering was reduced to $1.35 per share in October 2023 upon the issuance of shares of common stock sold pursuant to the Sales Agreement, and was subsequently reduced to $0.9702 per share in November 2023 upon the closing of the October 2023 Registered Direct Offering due to the issuance of warrants at an exercise price of $0.9702 per share.

Warrants to acquire shares of common stock primarily consist of equity-classified warrants. In addition, warrants to acquire shares of common stock that may require the Company to settle in cash are liability-classified warrants.

Warrants Classified as Equity

The warrants to acquire shares of common stock issued during the February 2023 Offering were recorded as equity upon issuance. During its evaluation of equity classification of these warrants, the Company considered the conditions as prescribed within ASC 815-40, Derivatives and Hedging, Contracts in an Entity’s own Equity (“ASC 815-40”). The conditions within ASC 815-40 are not subject to a probability assessment. The warrants to acquire shares of common stock do not fall under the liability criteria within ASC 480, Distinguishing Liabilities from Equity, as they are not puttable and do not represent an instrument that has a redeemable underlying security. The warrants do meet the definition of a derivative instrument under ASC 815 but are eligible for the scope exception as they are indexed to the Company’s own stock and would be classified in permanent equity if freestanding.

On February 28, 2023, in connection with closing of the February 2023 Offering, the Company entered into amendments to an aggregate of 3,438,851 warrants, which had been previously issued by the Company in an underwritten public offering that closed on April 5, 2022 (the "April 2022 Offering"), to reduce the exercise price of such warrants from $5.40 to $3.62, the average closing price of the Company’s common stock, as reported on the Nasdaq Capital Market, for the five trading days immediately preceding the pricing of the February 2023 Offering. The Company accounted for the amendment as a cost to issue equity with the incremental fair value of approximately $0.3 million recognized as an offset to the proceeds received. However, there was no net impact to the consolidated statements of stockholders' equity because the warrants are equity classified.

In November 2023, in connection with the closing of the October 2023 Registered Direct Offering, the Company entered into an amendment to reduce the exercise price of warrants to purchase up to 887,000 shares of the Company’s common stock which were issued in the April 2022 Offering and held by the purchaser in the

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued

(Unaudited)

October 2023 Registered Direct Offering to $0.9702 per share, and amended the termination date of such warrants to November 2, 2028.

Warrants Classified as Liabilities

Liability-classified warrants consist of warrants to acquire common stock issued in connection with certain previous equity financings. These warrants may be settled in cash and were determined not to be indexed to the Company’s common stock.

~~Table of Contents~~

~~SELLAS LIFE SCIENCES GROUP, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued~~

~~(Unaudited)~~

The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the consolidated statement of operations as change in fair value of warrant liability. The fair value of the warrants is estimated using a Black-Scholes pricing model with the following inputs:


		June 30, 2023			December 31, 2022				September 30, 2023			December 31, 2022
Risk free interest rate	Risk free interest rate	5.44		%	4.75		%	Risk free interest rate	5.55		%	4.75		%
Volatility	Volatility	65.03		%	120.60		%	Volatility	77.15		%	120.60		%
Expected term (years)	Expected term (years)	0.25			0.75			Expected term (years)	0.09			0.75
Expected dividend yield	Expected dividend yield	—		%	—		%	Expected dividend yield	—		%	—		%
Strike price	Strike price	$	7.50		$	7.50		Strike price	$	7.50		$	7.50

The expected volatility assumptions are based on the Company's implied volatility in combination with the implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the zero-coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is zero, because the Company has no present intention to pay cash dividends.

The changes in fair value of the warrant liability for the ~~six~~nine months ended ~~June~~September 30, 2023 were as follows (in thousands):


Warrant liability, December 31, 2022	$	4


Change in fair value of warrants	(4)
Warrant liability, ~~June~~September 30, 2023	$	—

10. Licensing Revenue

Exclusive License Agreement with 3D Medicines Inc.

In partial consideration for the rights granted by the Company, 3DMed agreed to pay the Company (i) a one-time upfront cash payment of $7.5 million, and (ii) milestone payments totaling up to $194.5 million in the aggregate upon the achievement of certain technology transfer, development and regulatory milestones, as well as sales milestones based on certain net sales thresholds of GPS Licensed Products in the 3DMed Territory in a given

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued

(Unaudited)

calendar year. 3DMed also agreed to pay tiered royalties based upon a percentage of annual net sales of GPS Licensed Products in the 3DMed Territory ranging from the high single digits to the low double digits.

Revenue Recognition

~~The~~At the inception of the 3DMed License Agreement, the Company ~~determined the~~recognized an initial transaction price of ~~the single performance obligation to be~~ $9.5 million as licensing revenue, which included the $7.5 million upfront fee as well as $2.0 million in development milestones that were assessed as probable of being achieved, at the inception of the 3DMed License Agreement and therefore were not constrained. As of December 31, 2021, the full $9.5 million initial transaction price was fully recognized as licensing revenue. The

~~Table of Contents~~

~~SELLAS LIFE SCIENCES GROUP, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued~~

~~(Unaudited)~~

~~Company determined that~~while the remaining ~~$192.5~~milestones were variable consideration subject to constraint at inception. In the first quarter of 2022, an additional $1.0 million in ~~certain~~licensing revenue was recognized upon approval by China’s National Medical Products Administration (“NMPA”) for a small Phase 1 clinical trial investigating safety of GPS in China.

There is $191.5 million in potential future development, regulatory, and sales milestones, isnot including future royalties, remaining under the 3DMed License Agreement as of September 30, 2023, which milestones are variable ~~consideration subject to constraint at inception.~~in nature and not under the Company's control. At the end of each reporting period, the Company reevaluates the probability of achievement of the future development, regulatory, and sales milestones subject to constraint and, if necessary, will adjust its estimate of the overall transaction price. Any such adjustments will be recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.

On March 31, 2022, the Company announced that an IND application filed by 3DMed, pursuant to its 3DMed License Agreement for GPS, for a small Phase 1 clinical trial investigating safety of GPS in China was approved by China's National Medical Products Administration ("NMPA"). The IND approval by the NMPA triggered a $1.0 million milestone payment to the Company which was recognized as licensing revenue in the first quarter of 2022. An additional $191.5 million in potential future development, regulatory, and sales milestones, not including future royalties, remains under the 3DMed License Agreement as of June 30, 2023, which milestones are variable in nature and not under the Company's control.

For the sales-based royalties, the Company will recognize revenue when the related sales occur. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.

There was no licensing revenue recognized during each of the three months ended ~~June~~September 30, 2023 and 2022. There was no licensing revenue recognized during the ~~six~~nine months ended ~~June~~September 30, 2023, and $1.0 million licensing revenue recognized during the ~~six~~nine months ended ~~June~~September 30, 2022 related to the IND approval by the NMPA.

There was no cost of licensing revenue recognized during each of the three months ended ~~June~~September 30, 2023 and 2022. There was no cost of licensing revenue recognized during the ~~six~~nine months ended ~~June~~September 30, 2023, and $0.1 million in cost of licensing revenue for the ~~six~~nine months ended ~~June~~September 30, 2022 for sublicensing fees incurred in connection with the 3DMed License Agreement.

11. Stock-Based Compensation

2017 Equity Incentive Plan

On December 29, 2017, the 2017 Equity Incentive Plan was approved by the stockholders of the Company, which currently allows for issuance of up to approximately 22,000 shares of common stock underlying stock options granted prior to September 10, 2019. The 2017 Equity Incentive Plan was terminated upon the approval of the 2019 Incentive Plan subject to outstanding stock options granted under the 2017 Equity Incentive Plan that remain exercisable through maturity for the Company's employees and directors.

2023 Amended and Restated Equity Incentive Plan

On September 10, 2019, the 2019 Equity Incentive Plan ("2019 Equity Plan") was approved by the stockholders of the Company, which currently allows for issuance of up to approximately 6,036,000 shares of common stock in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate.

The number of shares reserved for issuance under the 2019 Equity Plan automatically increased on January 1 of each year, for a period of four years, which commenced on January 1, 2020 and ended on (and including) January 1, 2023, by an amount equal to the lesser of (i) 5% of the total number of shares of common stock outstanding at the end of the prior fiscal year; and (ii) an amount determined by the board of directors or authorized committee.

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued

(Unaudited)

On June 20, 2023, an amendment to the 2019 Equity Plan was approved by the stockholders of the Company, which amended and restated the 2019 Equity Plan (as amended and restated, the "2023 Amended and Restated Equity Incentive Plan") to increase the number of shares of common stock authorized for issuance under the 2019 Equity Plan by 3,000,000 shares.

~~Table of Contents~~

~~SELLAS LIFE SCIENCES GROUP, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued~~

~~(Unaudited)~~

As of ~~June~~September 30, 2023, approximately ~~3,883,000~~3,905,000 shares of common stock were reserved for future grants under the 2023 Amended and Restated Equity Incentive Plan.

The following table summarizes the components of stock-based compensation expense in the consolidated statements of operations for the three and ~~six~~nine months ended ~~June~~September 30, 2023 and 2022, respectively (in thousands):


		Three Months Ended June 30,				Six Months Ended June 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2023		2022		2023		2022			2023		2022		2023		2022
Research and development	Research and development	$	92	$	70	$	188	$	125	Research and development	$	93	$	72	$	281	$	197
General and administrative	General and administrative	422		380		866		700		General and administrative	450		383		1,316		1,083
Total stock-based compensation	Total stock-based compensation	$	514	$	450	$	1,054	$	825	Total stock-based compensation	$	543	$	455	$	1,597	$	1,280

Options to Purchase Shares of Common Stock

The following table summarizes stock option activity of the Company for the ~~six~~nine months ended ~~June~~September 30, 2023:


		Total Number of Shares (In Thousands)	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (In Years)	Aggregate Intrinsic Value (In Thousands)			Total Number of Shares (In Thousands)	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (In Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2022	Outstanding at December 31, 2022	1,040	$	7.57		$	91	Outstanding at December 31, 2022	1,040	$	7.57		$	91
Granted	Granted	682	3.20					Granted	682	3.20

Canceled	Canceled	(57)	5.66					Canceled	(79)	5.28
Outstanding at June 30, 2023		1,665	$	5.85	8.63	$	1
Options exercisable at June 30, 2023		527	$	9.58	7.62	$	—
Outstanding at September 30, 2023								Outstanding at September 30, 2023	1,643	$	5.87	8.40	$	3
Options exercisable at September 30, 2023								Options exercisable at September 30, 2023	586	$	9.08	7.49	$	—

The aggregate intrinsic values of outstanding and exercisable stock options at ~~June~~September 30, 2023 were calculated based on the closing price of the Company’s common stock as reported on the Nasdaq Capital Market on ~~June 30,~~September 29, 2023 of ~~$1.57~~$1.64 per share. The aggregate intrinsic value equals the positive difference between the closing fair market value of the Company’s common stock and the exercise price of the underlying stock options.

The Company uses the Black-Scholes option-pricing model to determine the fair value of all its stock options granted. The weighted average assumptions used during the three and ~~six~~nine months ended ~~June~~September 30, 2023 and 2022, respectively, were as follows:

Three Months Ended June 30, Six Months Ended June 30,
2023 2022 2023 2022
Risk free interest rate 3.69 % 2.87 % 3.78 % 1.80 %
Volatility 129.55 % 144.75 % 127.77 % 130.60 %
Expected lives (years) 6.25 6.25 6.20 6.21
Expected dividend yield — % — % — % — %

The weighted-average grant date fair value of options granted during the three months ended June 30, 2023 and 2022 was $1.45 and $2.13, respectively. The weighted-average grant date fair value of options granted during the six months ended June 30, 2023 and 2022 was $2.88 and $4.76, respectively.


	Three Months Ended September 30,			Nine Months Ended September 30,
	2023	2022		2023		2022
Risk free interest rate	n/a	3.00	%	3.78	%	1.95	%
Volatility	n/a	138.57	%	127.77	%	131.54	%
Expected lives (years)	n/a	6.03		6.20		6.18
Expected dividend yield	n/a	—	%	—	%	—	%

Table of Contents

SELLAS LIFE SCIENCES GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued

(Unaudited)

There were no options granted during the three months ended September 30, 2023. The weighted-average grant date fair value of options granted during the three months ended September 30, 2022 was $2.78. The weighted-average grant date fair value of options granted during the nine months ended September 30, 2023 and 2022 was $2.88 and $4.52, respectively.

The Company’s expected common stock price volatility assumption is based upon the Company's own implied volatility in combination with the implied volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method, which averages the contractual term of the Company’s options of ten years with the average vesting term of four years for an average of approximately six years. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is zero because the Company has never paid cash dividends and presently has no intention to do so. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The Company accounts for forfeitures as they occur.

As of ~~June~~September 30, 2023, there was ~~$3.8~~$3.4 million of unrecognized compensation cost related to outstanding stock options that is expected to be recognized as a component of the Company’s operating expenses over a weighted-average period of ~~2.72~~2.53 years.

Time-vested RSUs and RSUs with Performance Conditions

The following table summarizes RSU activity of the Company for the ~~six~~nine months ended ~~June~~September 30, 2023:


		Shares (In Thousands)	Weighted Average Grant Date Fair Value			Shares (In Thousands)	Weighted Average Grant Date Fair Value
Unvested at December 31, 2022	Unvested at December 31, 2022	255	$	3.25	Unvested at December 31, 2022	255	$	3.25
Granted	Granted	195	$	3.34	Granted	195	$	3.34
Canceled	Canceled	(17)	$	3.76	Canceled	(17)	$	3.76
Unvested at June 30, 2023		433	$	3.27
Unvested at September 30, 2023					Unvested at September 30, 2023	433	$	3.27

As of ~~June~~September 30, 2023, there was ~~$1.2~~$1.1 million of unrecognized compensation cost related to outstanding RSUs that is expected to be recognized as a component of the Company's operating expenses over a weighted-average period of ~~2.98~~2.36 years. No RSUs vested during the ~~six~~nine months ended ~~June~~September 30, 2023.

2021 Employee Stock Purchase Plan

On April 22, 2021, the Board of Directors adopted the 2021 Employee Stock Purchase Plan ("2021 ESPP") which was approved by the Company's stockholders on June 8, 2021 and authorized the issuance of up to 300,000 shares of common stock pursuant to the 2021 ESPP. The 2021 ESPP allows employees to contribute up to 20% of their cash earnings, subject to a maximum of $25,000 per year under Internal Revenue Service rules, to be used to purchase shares of the Company’s common stock on semi-annual purchase dates. The 2021 ESPP allows eligible employees to purchase shares of common stock at a price per share equal to 85% of the lower of the fair market value of the common stock at the beginning or end of each six-month offering period during the term of the 2021 ESPP.

During the ~~six~~three and nine months ended ~~June~~September 30, 2023, ~~45,416~~46,038 and 91,454 shares of common stock, respectively, were purchased by employees under the 2021 ESPP for proceeds of approximately ~~$53,000.~~$54,000 and $107,000, respectively. There are currently ~~229,495~~183,457 shares of common stock reserved for issuance under the 2021 ESPP as of ~~June~~September 30, 2023.

12. Subsequent Events

The Company evaluated all events or transactions that occurred after ~~June~~September 30, 2023 up through the date these consolidated financial statements were issued. Other than as disclosed elsewhere in the notes to the consolidated financial statements, the Company did not have any material subsequent events.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This management’s discussion and analysis of financial condition as of ~~June~~September 30, 2023 and results of operations for the three and ~~six~~nine months ended ~~June~~September 30, 2023 and 2022, respectively, should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission, or SEC, on March 16, 2023, or our 2022 Annual Report, and our other public reports filed with the SEC.

Overview

We are a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. Our product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and SLS009 (formerly GFH009), a highly selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Galinpepimut-S, or GPS: Highly Novel and Engineered Immunotherapy Targeting the WT1 Antigen

Our lead product candidate, GPS, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the WT1 protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications.

In January 2020, we commenced in the United States an open label randomized Phase 3 clinical trial, the REGAL study, for GPS monotherapy in patients with acute myeloid leukemia, or AML, in the maintenance setting after achievement of second complete remission, or CR2, following successful completion of second-line antileukemic therapy. Patients are randomized (1:1) to receive either GPS or best available treatment, or BAT. We expect this study will be used as the basis for submission of a Biologics License Application, or BLA, subject to a statistically significant and clinically meaningful data outcome and agreement with the U.S. Food and Drug Administration, or the FDA. The primary endpoint of the clinical trial is overall survival. We plan to enroll approximately 125 to 140 patients at approximately 95 clinical sites in North America, Europe and Asia with a planned interim safety, efficacy and futility analysis after 60 events (deaths). We expect to complete enrollment in the REGAL study, other than the approximately 20 to 25 patients anticipated to be enrolled in China, in November 2023. Under our current assumptions with respect to completion of enrollment and the estimated survival times for both the treated and control groups in the study, we believe, after previous discussions with our external statisticians and experts, that the planned interim analysis after 60 events (deaths) per the protocol will occur by the end of 2023 or early 2024 and the final analysis after 80 events will occur by the end of 2024. ItThe number of patients needed for the events for the pre-specified interim and final analyses have already been enrolled, but it is important to note that because these analyses are event driven, they may occur at a different time than currently expected.

In December 2020, we entered into an exclusive license agreement, or 3DMed License Agreement, with 3D Medicines Inc., or ~~3D Medicines,~~3DMed, a China-based biopharmaceutical company developing next-generation immuno-oncology drugs, for the development and commercialization of GPS, as well as the Company’s next generation heptavalent immunotherapeutic GPS+, which is at preclinical stage, across all therapeutic and diagnostic uses in mainland China, Hong Kong, Macau and Taiwan, which we collectively refer to as Greater China, or the 3DMed Territory. We have retained sole rights to GPS and GPS+ outside of Greater China. In November 2022, we announced that we have agreed with ~~3D Medicines~~3DMed for ~~3D Medicines~~3DMed to participate in the REGAL study through the inclusion of approximately 20 to 25 patients from mainland China. Such participation by ~~3D Medicines~~3DMed, which we expect to occur in the fourth quarter of 2023, subject to any further delays due to supply chain or other operational reasons, will trigger two development milestone payments totaling $13.0 million ~~which we expect to receive in the third quarter of 2023.~~. If the REGAL study meets its primary endpoint for efficacy and the Chinese regulatory authorities determine that the REGAL data is sufficient for approval in China, GPS could potentially reach the market in Greater China much earlier than we and ~~3D Medicines~~3DMed had anticipated when we entered into the license agreement in December 2020. As of ~~June~~September 30, 2023, we have received an aggregate of $10.5 million in upfront and milestone payments under our license agreement with ~~3D Medicines~~3DMed and a total of $191.5 million in

potential future development, regulatory and sales milestones, not including future royalties, remains under the license agreement, which milestones are variable in nature and not under our control.

In December 2018, pursuant to a Clinical Trial Collaboration and Supply Agreement, we initiated a Phase 1/2 multi-arm "basket" type clinical study of GPS in combination with Merck & Co., Inc.’s anti-PD-1 therapy,

pembrolizumab (Keytruda). In 2020, we, together with Merck, determined to focus on ovarian cancer (second or third line). In November 2022, we reported topline clinical and initial immune response data from this study, which showed that treatment with the combination of GPS and pembrolizumab compared favorably to treatment with anti-PD-1 therapy alone in a similar patient population. We ~~plan to present~~presented final data from this study at a medical conference in ~~the fourth quarter of~~November 2023.

In February 2020, a Phase 1 open-label investigator-sponsored clinical trial of GPS, in combination with Bristol-Myers Squibb’s anti-PD-1 therapy, nivolumab (Opdivo), in patients with malignant pleural mesothelioma, or MPM, who harbor relapsed or refractory disease after having received frontline standard of care multimodality therapy was commenced at MSK. Enrollment of a target total of 10 evaluable patients was completed at the end of 2022. In June 2023, we reported that the primary endpoint of safety and the efficacy endpoint were both met with clinical activity and increased survival in this study. Additional immune response data from all 10 evaluable patients is expected in the fourth quarter of 2023.

GPS was granted Orphan Drug Product Designations, or ODD, from the FDA, as well as Orphan Medicinal Product Designations from the European Medicines Agency, or EMA, for GPS in AML, MPM, and multiple myeloma, or MM, as well as Fast Track Designation for AML, MPM, and MM from the FDA.

SLS009: Highly Selective Next Generation CDK9 Inhibitor

On March 31, 2022, we entered into an exclusive license agreement, or the SLS009 Agreement, with GenFleet Therapeutics (Shanghai), Inc., or GenFleet, a clinical-stage biotechnology company developing cutting-edge therapeutics in oncology and immunology, that grants rights to us for the development and commercialization of SLS009, a highly selective small molecule CDK9 inhibitor, across all therapeutic and diagnostic uses worldwide, except for Greater China.

CDK9 activity has been shown to correlate negatively with overall survival in a number of cancer types, including hematologic cancers, such as AML and lymphomas, as well as solid cancers, such as osteosarcoma, pediatric soft tissue sarcomas, melanoma, endometrial, lung, prostate, breast and ovarian. As demonstrated in preclinical and clinical data, to date, SLS009’s high selectivity has the potential to reduce toxicity as compared to older CDK9 inhibitors and other next-generation CDK9 inhibitors currently in clinical development and to potentially be more efficacious.

In ~~April~~the second quarter of 2023, we announced the completion of the safety evaluation stage of the highest dose cohort of patients with AML who relapsed after or were refractory to available antileukemic therapies in our Phase 1 dose escalation clinical trial of SLS009. No further dose escalations are planned in the AML group, while dose escalation continues in the lymphoma group with the addition of 75 mg and 100 mg once-a-week dose cohorts. The 100 mg cohort is planned to likely be the highest dose level for the lymphoma group. In the third quarter of 2023, we expect enrollment in the lymphoma group to be completed and to report clinical activity observed in the lymphoma group. In May 2023, we announcedSLS009 as well as positive topline data, ~~from this study for the group of patients with AML~~ and that the recommended Phase 2 dose, or RP2D, in AML, was established at 60 mg and submitted to the U.S. Food and Drug Administration.

~~In June 2023, we~~ We also announced that the first patient was dosed in a Phase 2a clinical trial with SLS009 in combination with venetoclax and azacitidine, or aza/ven, in patients with AML who relapsed after or are refractory to treatment with venetoclax-based therapies. The trial is an open label, single arm, multi-center study that is designed to evaluate safety, tolerability, and efficacy at two dose levels of SLS009 (once weekly 45 mg or 60 mg) in combination with aza/ven. In addition to safety and tolerability of SLS009 in combination with aza/ven, the primary endpoints are complete response composite rate and duration of response. Additional endpoints include event free survival, overall survival, and pharmacokinetic and pharmacodynamic assessments. The trial includes several sites in the United States, will enroll up to 20 patients and, based on initial results, may be expanded into a registrational trial. ~~Topline~~

In October 2023, we announced positive initial topline data at the 45 mg (safety) dose level from ~~this study~~the Phase 2a study. Six of the seven patients are alive as of the latest follow-up, and five remain on treatment. The first patient enrolled achieved a complete response and is in the sixth month of treatment, while the second enrolled patient remains alive and is in the fifth month of treatment. Anti-leukemic effects have been observed in all patients without any significant safety issues to date. Additional topline data for the 45 mg dose and for the recommended Phase 2 dose (60mg) is expected in the fourth quarter of ~~2023.~~

We are also planning to potentially commence a Phase 2 clinical trial of SLS009 in certain solid tumors and/or lymphoma in the fourth quarter of 2023 and are exploring various options with respect to clinical development for SLS009 in several pediatric indications.2024.

In September 2023, we announced positive topline data for the patient group with relapsed/refractory (r/r) lymphomas from the Phase 1 dose-escalation trial of SLS009 as well as the RP2D of 100 mg for this patient population. All primary and secondary study objectives, including safety, clinical activity, pharmacokinetics (PK), and pharmacodynamics (PD), were successfully achieved for the group of patients with lymphomas. Among 34 evaluable r/r lymphoma patients, five (14.7%) achieved a clinical response with a reduction of tumor burden of up to 68.9%. An additional seven patients (20.6%) achieved stable disease resulting in an overall disease control rate (clinical response plus stable disease) of 35.3%. In the subset of patients with peripheral T-cell lymphomas, or PTCL, four out of 11 (36.4%) evaluable patients achieved a clinical response. Additionally, one patient achieved a complete response in late October 2023 and remains on the trial after 16 weeks of treatment. In October 2023 we announced that our partner, GenFleet, dosed the first patient in a Phase 1b/2 trial evaluating SLS009 in patients with relapsed/refractory PTCL. The open-label, single-arm trial will enroll up to 95 patients to evaluate safety and efficacy and, based on the results, may serve as a registrational study. This initial PTCL study is fully funded by GenFleet and is being conducted in China.

SLS009 is also currently being evaluated in pediatric solid tumors and leukemia models through the NCI Pediatric Preclinical in Vivo Testing, or PIVOT, program. Studies are supported through cooperative agreement grants from the NCI to the seven PIVOT research programs performing the PK and efficacy testing in pediatric tumors and a centralized coordinating center. Preclinical data are scheduled to be generated continuously through the remainder of 2023 and the first half of 2024.

In October 2023, we announced that SLS009 was granted ODD for AML and Fast Track Designation for PTCL by the FDA.

Components of Results of Operations

Licensing Revenue

Licensing revenue consists of revenue recognized pursuant to the 3DMed License Agreement. In the future, we may generate revenue from a combination of reimbursements, up-front payments, milestone payments and royalties in connection with the 3DMed License Agreement.

Cost of Licensing Revenue

Cost of licensing revenue consists of sublicensing fees incurred under our license from MSK in connection with the 3DMed License Agreement.

Research and Development

Research and development expense consists of expenses incurred in connection with the discovery and development of our product candidates. We expense research and development costs as incurred. These expenses include:

•expenses incurred under agreements with CROs, as well as investigative sites and consultants that conduct our preclinical studies and clinical trials;

•manufacturing and clinical drug supply expenses;

•outsourced professional scientific development services;

•employee-related expenses, which include salaries, benefits and stock-based compensation;

•payments made under our license agreements, under which we acquired certain intellectual property;

•expenses relating to certain regulatory activities, including filing fees paid to regulatory agencies;

•laboratory materials and supplies used to support our research activities; and

•allocated expenses, utilities, and other facility-related costs.

The successful development of our current and future product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the remainder of the development of, or when, if ever, material net cash inflows may commence from, any current or future product candidates. This uncertainty is due to the numerous risks and uncertainties associated with the duration and cost of our clinical trials, which vary significantly over the life of a project as a result of many factors, including:

•the number and geographical location of clinical sites included in the trials;

•the length of time required to enroll suitable patients;

•the number and geographical location of patients that ultimately participate in the trials;

•the number of doses patients receive;

•the duration of patient follow-up;

•the results of clinical trials;

•the expenses associated with manufacturing and clinical drug supply;

•the receipt of marketing approvals; and

•the commercialization of current and future product candidates.

Research and development activities are central to our business model. Oncology product candidates in the later stages of clinical development generally have higher development costs than those in the earlier stages of clinical development, primarily due to the increased size and duration of the later-stage clinical trials. We expect our research and development expenses to increase for the foreseeable future as we conduct and complete our ongoing early and late-stage clinical trials and initiate additional clinical trials.

Our expenditures are subject to additional uncertainties, including the terms and timing of regulatory approvals. We may never succeed in achieving regulatory approval for any of our current or future product candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or target indications or focus on others. A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development.

General and Administrative

General and administrative expenses consist principally of salaries and related costs for personnel in executive, administrative, finance and legal functions, including stock-based compensation, travel expenses and recruiting expenses, fees for outside legal counsel, amortization of contract acquisition costs (commissions), and director and officer insurance premiums. Other general and administrative expenses include facility related costs, patent filing and prosecution costs, professional fees for business development, accounting, consulting, legal and tax-related services associated with maintaining compliance with our Nasdaq listing and SEC reporting requirements, investor relations costs, and other expenses associated with being a public company.

If and when we believe that regulatory approval of a product candidate appears likely, we anticipate that an increase in general and administrative expenses will occur as a result of our preparation for commercial operations, particularly as it relates to the sales and marketing of such product candidate. Oncology product commercialization may take several years and millions of dollars in development costs.

Acquired In-Process Research and Development

Acquired in-process research and development consists of costs to acquire or license product candidates from third-parties for development with no alternative future use.

Non-Operating Income

Non-operating income consists of changes in fair value of our warrant liability, changes in fair value of our contingent consideration, and interest income. Interest income primarily reflects interest earned from our cash and cash equivalents.

Critical Accounting Policies and Estimates

In the 2022 Annual Report, we disclosed our critical accounting policies and estimates upon which our consolidated financial statements are derived. There have been no material changes to these policies and estimates since December 31, 2022 that are not included in Note 3 of the accompanying consolidated financial statements for the ~~six~~nine months ended ~~June~~September 30, 2023. Readers are encouraged to read the 2022 Annual Report in conjunction with this Quarterly Report on Form 10-Q.

Results of Operations for the Three and ~~Six~~Nine Months Ended ~~June~~September 30, 2023 and 2022

The following table summarizes our results of operations for the three and ~~six~~nine months ended ~~June~~September 30, 2023 and 2022 (in thousands):


		Three Months Ended June 30,							Three Months Ended September 30,
		2023		2022		Change			2023		2022		Change
Licensing revenue	Licensing revenue	$	—	$	—	$	—	Licensing revenue	$	—	$	—	$	—
Operating expenses:	Operating expenses:							Operating expenses:
Cost of licensing revenue	Cost of licensing revenue	—		—		—		Cost of licensing revenue	—		—		—
Research and development	Research and development	5,923		5,529		394		Research and development	5,813		4,282		1,531
General and administrative	General and administrative	3,127		3,094		33		General and administrative	3,548		2,864		684

Total operating expenses	Total operating expenses	9,050		8,623		427		Total operating expenses	9,361		7,146		2,215
Operating loss	Operating loss	(9,050)		(8,623)		(427)		Operating loss	(9,361)		(7,146)		(2,215)
Non-operating income	Non-operating income	210		209		1		Non-operating income	94		124		(30)
Net loss	Net loss	$	(8,840)	$	(8,414)	$	(426)	Net loss	$	(9,267)	$	(7,022)	$	(2,245)


		Six Months Ended June 30,							Nine Months Ended September 30,
		2023		2022		Change			2023		2022		Change
Licensing revenue	Licensing revenue	$	—	$	1,000	$	(1,000)	Licensing revenue	$	—	$	1,000	$	(1,000)
Operating expenses:	Operating expenses:							Operating expenses:
Cost of licensing revenue	Cost of licensing revenue	—		100		(100)		Cost of licensing revenue	—		100		(100)
Research and development	Research and development	13,097		10,140		2,957		Research and development	18,910		14,422		4,488
General and administrative	General and administrative	7,234		6,118		1,116		General and administrative	10,782		8,982		1,800
Acquired in-process research and development	Acquired in-process research and development	—		10,000		(10,000)		Acquired in-process research and development	—		10,000		(10,000)
Total operating expenses	Total operating expenses	20,331		26,358		(6,027)		Total operating expenses	29,692		33,504		(3,812)
Operating loss	Operating loss	(20,331)		(25,358)		5,027		Operating loss	(29,692)		(32,504)		2,812
Non-operating income	Non-operating income	394		200		194		Non-operating income	488		324		164
Net loss	Net loss	$	(19,937)	$	(25,158)	$	5,221	Net loss	$	(29,204)	$	(32,180)	$	2,976

Further analysis of the changes and trends in our operating results are discussed below.

Licensing Revenue

There was no licensing revenue for each of the three months ended ~~June~~September 30, 2023 and 2022.

There was no licensing revenue for the ~~six~~nine months ended ~~June~~September 30, 2023. Licensing revenue was $1.0 million for the ~~six~~nine months ended ~~June~~September 30, 2022 and was related to China's National Medical Products Administration, or NMPA, approving an IND application for a small Phase I clinical trial investigating safety of GPS in China, which triggered a development milestone under the 3DMed License Agreement.

Cost of Licensing Revenue

There was no cost of licensing revenue for each of the three months ended ~~June~~September 30, 2023 and 2022.

There was no cost of licensing revenue for the ~~six~~nine months ended ~~June~~September 30, 2023. We incurred $0.1 million of sublicensing fees payable under our license from MSK in connection with the 3DMed License Agreement during the ~~six~~nine months ended ~~June~~September 30, 2022.

~~Research and Development~~

Research and Development

Research and development expenses were ~~$5.9~~$5.8 million for the three months ended ~~June~~September 30, 2023 compared to ~~$5.5~~$4.3 million for the three months ended ~~June~~September 30, 2022. The ~~$0.4~~$1.5 million increase was primarily attributable to a ~~$0.6 million increase in clinical and regulatory consulting expenses, a $0.4~~$0.7 million increase in clinical trial expenses related to our Phase 3 REGAL clinical trial of GPS and our Phase 2a and Phase 1 clinical trials of SLS009, a $0.3 million increase in manufacturing expenses related to clinical drug supply purchases, a $0.3 million increase in clinical and regulatory consulting expenses, and a ~~$0.3~~$0.2 million increase in personnel related expenses due to increased headcount. We anticipate that our research and development expenses will increase in the future as we continue to advance the development of GPS and SLS009, including our Phase 3 clinical trial of GPS in AML and the ongoing and planned clinical trials of SLS009.

Research and development expenses were $18.9 million for the nine months ended September 30, 2023 compared to $14.4 million for the nine months ended September 30, 2022. The $4.5 million increase was primarily attributable to a $2.0 million increase in clinical trial expenses related to our Phase 3 REGAL clinical trial of GPS and our Phase 2a and Phase 1 clinical trials of SLS009, a $1.7 million increase in clinical and regulatory consulting expenses, and a $1.0 million increase in personnel related expenses due to increased headcount. These increases were partially offset by a ~~$0.9~~$0.2 million decrease in manufacturing expenses primarily due to the timing of athe manufacturing of a registration batch of GPS in the prior period. We anticipate that our research and development expenses will increase in the future as we continue to advance the development of GPS and SLS009, including our Phase 3 clinical trial of GPS in AML and the ongoing ~~Phase 2a~~ and ~~Phase 1 clinical trials of SLS009.~~

Research and development expenses were $13.1 million for the six months ended June 30, 2023 compared to $10.1 million for the six months ended June 30, 2022. The $3.0 million increase was primarily attributable to a $1.4 million increase in clinical and regulatory consulting expenses, a $1.2 million increase in clinical trial related expenses related to our ongoing Phase 3 REGAL clinical trial of GPS and our Phase 2a and Phase 1 clinical trials of SLS009, and a $0.8 million increase in personnel related expenses due to increased headcount. These increases were partially offset by a $0.4 million decrease in manufacturing expenses primarily due to the timing of a manufacturing of a registration batch of GPS in the prior period. We anticipate that our research and development expenses will increase in the future as we continue to advance the development of GPS and SLS009, including our Phase 3 clinical trial of GPS in AML and the ongoing Phase 2a and Phase 1planned clinical trials of SLS009.

General and Administrative

General and administrative expenses were ~~$3.1~~$3.5 million for ~~each of~~ the three months ended ~~June~~September 30, 2023 ~~and~~compared to $2.9 million for the three months ended ~~June~~September 30, 2022. ~~There~~The $0.6 million increase was primarily attributable to a $0.2 million ~~decrease~~increase in outside services and public company costs, ~~which were offset by~~ a ~~$0.1~~$0.2 million increase in ~~personnel related expenses due to increased headcount~~legal and intellectual property fees, and a ~~$0.1~~$0.2 million increase in ~~office related expenses and~~ other general and administrative costs.

General and administrative expenses were ~~$7.2~~$10.8 million for the ~~six~~nine months ended ~~June~~September 30, 2023 compared to ~~$6.1~~$9.0 million for the ~~six~~nine months ended ~~June~~September 30, 2022. The ~~$1.1~~$1.8 million increase was primarily ~~due~~attributable to a ~~$0.6~~$0.7 million increase in personnel related expenses due to increased headcount, ~~including~~ a ~~$0.2 million increase in non-cash stock-based compensation, a $0.2~~$0.4 million increase in legal and intellectual property fees, a $0.4 million increase in outside services and public company costs, and a $0.3 million increase in ~~office related expenses and~~ other general and administrative costs.

Acquired In-Process Research and Development

There was no acquired in-process research and development expense during each of the three months ended ~~June~~September 30, 2023 and 2022.

There was no acquired in-process research and development expense during the ~~six~~nine months ended ~~June~~September 30, 2023. During the ~~six~~nine months ended ~~June~~September 30, 2022, we recognized $10.0 million for the acquisition of in-process research and development related to the in-licensing of SLS009.

Non-Operating Income

Non-operating income for the three and ~~six~~nine months ended ~~June~~September 30, 2023 and 2022, respectively, was as follows (in thousands):


		Three Months Ended June 30,						Six Months Ended June 30,							Three Months Ended September 30,						Nine Months Ended September 30,
		2023		2022		Change		2023		2022		Change			2023		2022		Change		2023		2022		Change
Change in fair value of warrant liability	Change in fair value of warrant liability	$	2	$	48	$	(46)	$	4	$	37	$	(33)	Change in fair value of warrant liability	$	—	$	2	$	(2)	$	4	$	39	$	(35)
Change in fair value of contingent consideration	Change in fair value of contingent consideration	—		115		(115)		—		115		(115)		Change in fair value of contingent consideration	—		11		(11)		—		126		(126)
Interest income	Interest income	208		46		162		390		48		342		Interest income	94		111		(17)		484		159		325
Total non-operating income	Total non-operating income	$	210	$	209	$	1	$	394	$	200	$	194	Total non-operating income	$	94	$	124	$	(30)	$	488	$	324	$	164

Non-operating income of ~~$0.2~~$0.1 million and ~~$0.4~~$0.5 million during the three and ~~six~~nine months ended ~~June~~September 30, 2023, respectively, was primarily interest income earned from our cash and cash equivalents.

Non-operating income of ~~$0.2~~$0.1 million during ~~each of~~ the three ~~and six~~ months ended ~~June~~September 30, 2022 was ~~primarily~~ due to ~~decreases~~interest income earned from our cash and cash equivalents. Non-operating income of $0.3 million during the nine months ended September 30, 2022 was due to interest income earned from our cash and cash equivalents, a decrease in the fair value of the contingent consideration liability driven by an increase in discount rates, and a decrease in the fair value of the warrant liability driven by a decrease in our common stock ~~price, and interest income earned from our cash and cash equivalents.~~price.

The change in fair value of warrant liability and change in fair value of contingent consideration are non-cash in nature.

Income Tax Expense

There was no income tax expense for the three and ~~six~~nine months ended ~~June~~September 30, 2023 and 2022. We continue to maintain a full valuation allowance against our net deferred tax assets.

Liquidity and Capital Resources

We did not generate any revenue from product sales during the ~~six~~nine months ended ~~June~~September 30, 2023 and 2022. Through ~~June~~September 30, 2023, we have only generated licensing revenue from the 3DMed License Agreement. Since inception, we have incurred net losses, used net cash in our operations, and have funded substantially all of our operations through proceeds of the sale of equity securities and convertible notes.

Sources of Liquidity

On October 30, 2023, we entered into a Securities Purchase Agreement, or the Purchase Agreement, with a single institutional investor, or the Investor, pursuant to which we agreed to issue and sell, in a registered direct offering by us directly to the Investor, or the October 2023 Registered Direct Offering, 3,100,000 shares of our common stock and 552,300 pre-funded warrants exercisable for shares of common stock, together with accompanying warrants to purchase an aggregate of 3,652,300 shares of common stock. Each share of common stock and accompanying warrant were sold together at a combined purchase price of $1.0952 and each pre-funded warrant and accompanying warrant were sold together at a combined purchase price of $1.0951. The aggregate gross proceeds to us from the October 2023 Registered Direct Offering were approximately $4.0 million, before deducting placement agents' fees and related offering expenses.

On February 28, 2023, we consummated an underwritten public offering, or the February 2023 Offering, issuing 7,220,217 shares of common stock and accompanying common stock warrants to purchase an aggregate of 7,220,217 shares of common stock. The shares of common stock and accompanying common stock warrants were sold at a combined price of $2.77 per share and accompanying common stock warrant. Each common stock warrant sold with the shares of common stock represents the right to purchase one share of our common stock at an exercise price of $2.77 per share. The common stock warrants are exercisable immediately and will expire on February 28, 2028, five years from the date of issuance. The net proceeds from the February 2023 Offering were approximately $18.5 million, after deducting underwriting discounts and commissions and offering expenses, and excluding the exercise of any warrants.

On April 16, 2021, we entered into a Controlled Equity OfferingSM Sales Agreement, or the Sales Agreement, with Cantor Fitzgerald & Co., or the Agent. From time to time during the term of the Sales Agreement, subject to certain restrictions, we may offer and sell shares of common stock having an aggregate offering price up to a total of $50.0 million in gross proceeds. The Agent will collect a fee equal to 3% of the gross sales price of all shares of common stock sold. Shares of common stock sold under the Sales Agreement are offered and sold pursuant to our registration statement on Form S-3, which was filed with the SEC on April 16, 2021 and declared effective on April 29, 2021. During the ~~six~~nine months ended ~~June~~September 30, 2023, we sold a total of 76,882 shares of common stock pursuant to the Sales Agreement at an average price of $3.59 per share for aggregate net proceeds of approximately $0.3 million. ~~There remains approximately $39.2 million available for future sales~~Subsequent to September 30, 2023, we sold a total of 16,000 shares of common stock ~~under~~pursuant to the Sales Agreement asfor aggregate net proceeds of ~~June 30, 2023. Other than the Sales Agreement, we currently do not have any commitments to obtain additional funds.~~approximately $21,000.

In December 2020, together with our wholly-owned subsidiary, SLSG Limited, LLC, we entered into the 3DMed License Agreement pursuant to which we granted 3DMed a sublicensable royalty-bearing license under certain intellectual property owned or controlled by us, to develop, manufacture and have manufactured, and commercialize GPS and heptavalent GPS product candidates for all therapeutic and other diagnostic uses in the

3DMed Territory. To date, we have received $10.5 million in upfront payments and certain technology transfer and regulatory milestones. ~~The~~In November 2022, we announced that we have agreed with 3D Medicines for 3D Medicines to participate in the REGAL study through the inclusion of approximately 20-25 patients from mainland China. Such participation by 3D Medicines, which we expect to occur in the fourth quarter of ~~3DMed in our REGAL Phase 3 clinical trial in China~~2023, subject to any further delays due to supply chain or other operational reasons, will trigger two development milestone payments totaling $13.0 ~~million to us, which we expect to receive in the third quarter of 2023.~~million. A total of $191.5 million in potential future development, regulatory, and sales milestones, not including future royalties, remains under the 3DMed License Agreement as of ~~June~~September 30, 2023, which milestones are all variable in nature and not under our control.

Funding Requirements

As of ~~June~~September 30, 2023, we had an accumulated deficit of ~~$199.8~~$209.1 million, cash and cash equivalents of ~~$13.8~~$4.0 million and restricted cash and cash equivalents of $0.1 million. In addition, we had current liabilities of ~~$13.4~~$11.7 million as of ~~June~~September 30, 2023. We expect that our cash and cash equivalents, together with the net proceeds from the October 2023 Registered Direct Offering, will not be sufficient to fund our current planned operations for at least the next twelve months from the date of issuance of these financial statements. The $13.0 million of development milestone payments to us triggered by 3DMed's participation in the REGAL study are variable in nature and not under our control, and therefore are not included in our going concern assumption. These conditions give rise to a substantial doubt over our ability to continue as a going concern. This going concern assumption is based on management’s assessment of the sufficiency of our current and future sources of liquidity and whether it is probable we will be able to meet our obligations as they become due for at least one year from the date our consolidated financial statements are available to be issued, and if not, whether our liquidation is imminent.

Our consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. We anticipate incurring additional losses until such time, if ever, that we can generate significant sales of any current or future product candidates in development.

We will require substantial additional financing to develop any current or future product candidates. If we are unable to obtain additional funding on a timely basis, we will be required to scale back our plans and place certain activities on hold. Other than the Sales Agreement, we currently do not have any commitments to obtain additional funds. Our management continues to evaluate different strategies to obtain the required funding for future operations. These strategies may include utilizing the Sales Agreement or public and private placements of equity and/or debt securities, ~~and~~which may be subject to lock-up, as well as payments from potential strategic research and development ~~collaborations.~~collaborations or licensing and/or marketing arrangements with pharmaceutical companies. Additionally, we continue to pursue discussions with global and regional pharmaceutical companies for licensing and/or co-development rights to our product candidates. There can be no assurance that these future funding efforts will be successful.

Our future operations are highly dependent on a combination of factors, including (i) the timely and successful completion of any additional financings, (ii) our ability to complete revenue-generating partnerships with pharmaceutical and biotechnology companies, (iii) the success of our research and development activities, (iv) the development of competitive therapies by other biotechnology and pharmaceutical companies, and, ultimately, (v) regulatory approval and market acceptance of our product candidates.

Cash Flows

The following table summarizes our cash flows from operating, investing, and financing activities for the ~~six~~nine months ended ~~June~~September 30, 2023 and 2022 (in thousands):

Six Months Ended June 30,
2023 2022
Net cash (used in) provided by:
Operating activities $ (19,693) $ (12,911)
Investing activities (2,500) (4,500)
Financing activities 18,875 23,043
Net (decrease) increase in cash, cash equivalents, restricted cash, and restricted cash equivalents $ (3,318) $ 5,632


	Nine Months Ended September 30,
	2023		2022
Net cash (used in) provided by:
Operating activities	$	(26,585)	$	(18,657)
Investing activities	(5,500)		(4,500)
Financing activities	18,929		23,150
Net decrease in cash, cash equivalents, restricted cash, and restricted cash equivalents	$	(13,156)	$	(7)

Net Cash Used in Operating Activities

Net cash used in operating activities of ~~$19.7~~$26.6 million during the ~~six~~nine months ended ~~June~~September 30, 2023 was primarily attributable to our net loss of $19.9 million and net change in our operating assets and liabilities of approximately $1.1 million, which were partially offset by various net non-cash charges of $1.3 million. The net change in our operating assets and liabilities of $1.1 million is primarily attributable to an increase in prepaid expenses and other current assets of $1.1 million. Net non-cash charges were driven by $1.1 million in non-cash stock-based compensation and expense and $0.2 million in non-cash lease expense.

~~Net cash used in operating activities of $12.9 million during the six months ended June 30, 2022 was primarily attributable to our net loss of $25.2~~$29.2 million, which was partially offset by various net non-cash charges of ~~$10.8~~$2.0 million and a net change in our operating assets and liabilities of approximately $0.6 million. Net non-cash charges were driven by $1.6 million in non-cash stock-based compensation expense and $0.4 million in non-cash lease expense. The net change in our operating assets and liabilities is primarily attributable to an increase in accounts payable and accrued expenses of approximately $1.6 million, partially offset by an increase in prepaid expenses and other current assets of approximately $0.6 million and a decrease in operating lease liabilities of approximately $0.4 million.

Net cash used in operating activities of $18.7 million during the nine months ended September 30, 2022 was primarily attributable to our net loss of $32.2 million, which was partially offset by various net non-cash charges of $11.4 million and the net change in our operating assets and liabilities of approximately ~~$1.5~~$2.1 million. Net non-cash charges were driven by $10.0 million in expense related to the acquired in-process research and development, ~~and $0.8~~$1.3 million in non-cash stock compensation ~~expense.~~expense, and $0.1 million in other net non-cash charges. The net change in our operating assets and liabilities of ~~$1.5~~$2.1 million is primarily attributable to ~~an increase in accounts payable of $1.2 million and~~ an increase in accrued expenses and other current liabilities of ~~$0.4~~$1.9 million, and a decrease in prepaid expenses and other current assets of $0.5 million, which were partially offset by a decrease in operating lease liabilities of ~~$0.1~~$0.3 million.

Net Cash Used in Investing Activities

Net cash used in investing activities of ~~$2.5~~$5.5 million during the ~~six~~nine months ended ~~June~~September 30, 2023 related to license payments made for the acquisition of in-process research and development under the GenFleet License Agreement.

Net cash used in investing activities of $4.5 million during the ~~six~~nine months ended ~~June~~September 30, 2022 related to license payments made for the acquisition of in-process research and development under the GenFleet License Agreement.

Net Cash Provided by Financing Activities

We generated $18.9 million in net cash from financing activities during the ~~six~~nine months ended ~~June~~September 30, 2023, which was due to approximately $18.5 million in net proceeds from the February 2023 Offering, $0.3 million in net proceeds under the Sales Agreement, and $0.1 million from the purchase of shares of common stock by employees under the 2021 Employee Stock Purchase Plan.

We generated ~~$23.0~~$23.2 million in net cash from financing activities during the ~~six~~nine months ended ~~June~~September 30, 2022 that was due to $23.0 million in aggregate net proceeds received from our underwritten public offering, which closed in April ~~2022.~~2022, $0.1 million in aggregate net proceeds received from the issuance of common stock under the Sale Agreement, and $0.1 million in aggregate net proceeds received from the issuance of common stock under the employee stock purchase plan.

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet financing arrangements as of ~~June~~September 30, 2023.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not applicable.

2829

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, our principal executive officer and our principal financial officer (the “Certifying Officers”), evaluated the effectiveness of our disclosure controls and procedures. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934 (the “Exchange Act”), such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Certifying Officers, as appropriate to allow timely decisions regarding required disclosure. Based on these evaluations, the Certifying Officers have concluded, that, as of the end of the period covered by this Quarterly Report on Form 10-Q:

(a)our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms; and

(b)our disclosure controls and procedures were effective to provide reasonable assurance that material information required to be disclosed by us in the reports we file or submit under the Exchange Act was accumulated and communicated to our management, including the Certifying Officers, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended ~~June~~September 30, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

2930

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Please refer to Note 7 (Commitments and Contingencies) to our consolidated financial statements contained in Part I, Item 1 (Financial Statements) of this Quarterly Report on Form 10-Q, which is incorporated into this item by reference.

ITEM 1A. RISK FACTORS

Please refer to our note on forward-looking statements on page 2 of this Quarterly Report on Form 10-Q, which is incorporated into this item by reference.

In addition to the other information set forth in this report, you should carefully consider the risk factors discussed in our 2022 Annual Report. The risks described in such 2022 Annual Report are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition, operating results and stock price.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

3031

ITEM 6. EXHIBITS

Exhibit
#

Description

Form

Exhibit

Filing Date

Exhibit
#

Description

Form

Exhibit

Filing Date

3.1

Composite Amended and Restated Certificate of Incorporation of the Registrant (formerly, Galena Biopharma, Inc.) amended as of December 27, 2017

10-K

3.1

April 13, 2018

3.1

Composite Amended and Restated Certificate of Incorporation of the Registrant (formerly, Galena Biopharma, Inc.) amended as of December 27, 2017

10-K

3.1

April 13, 2018

3.2

Amended and Restated By-Laws of the Registrant

8-K

3.3

January 5, 2018

3.2

Amended and Restated By-Laws of the Registrant

8-K

3.3

January 5, 2018

10.1

2023 Amended and Restated Equity Incentive Plan

10.2

Addendum to the Side Letter Agreement dated May 24, 2023 by and between the Registrant and 3DMedicines Inc.

31.1

Certification of Principal Executive Officer pursuant to Rule13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended.**

31.1

Certification of Principal Executive Officer pursuant to Rule13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended.**

31.2

Certification of Principal Financial Officer pursuant to Rule13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended.**

31.2

Certification of Principal Financial Officer pursuant to Rule13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended.**

32.1

Certification of Principal Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. ***

32.1

Certification of Principal Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. ***

32.2

Certification of Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. ***

32.2

Certification of Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. ***

101.INS

XBRL Instance Document.*

101.INS

XBRL Instance Document.*

101.SCH

XBRL Taxonomy Extension Schema.*

101.SCH

XBRL Taxonomy Extension Schema.*

101.CAL

XBRL Taxonomy Extension Calculation Linkbase.*

101.CAL

XBRL Taxonomy Extension Calculation Linkbase.*

101.DEF

XBRL Taxonomy Extension Definition Linkbase.*

101.DEF

XBRL Taxonomy Extension Definition Linkbase.*

101.LAB

XBRL Taxonomy Extension Label Linkbase.*

101.LAB

XBRL Taxonomy Extension Label Linkbase.*

101.PRE

XBRL Taxonomy Extension Presentation Linkbase.*

101.PRE

XBRL Taxonomy Extension Presentation Linkbase.*


*			Indicates management contract or compensatory plans or arrangements.
**			Filed herewith
***			The certifications attached as Exhibit 32.1 and Exhibit 32.2 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

3132

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


			SELLAS Life Sciences Group, Inc.

			By:						/s/ Angelos M. Stergiou

									Angelos M. Stergiou, MD, ScD h.c.
									President and Chief Executive Officer
									(Principal Executive Officer)

									Date: ~~August 10,~~November 9, 2023

			By:						/s/ John T. Burns

									John T. Burns, CPA
									Chief Financial Officer
									(Principal Financial and Principal Accounting Officer)

									Date: ~~August 10,~~November 9, 2023

3233